Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and other unmet clinical indications, today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational ...
Source: prnewswire.com